Status:
COMPLETED
Efficacy and Safety of ALGRX 4975 in Treatment of Postoperative Pain After Hernia Repair
Lead Sponsor:
AlgoRx Pharmaceuticals
Conditions:
Postoperative Pain
Eligibility:
MALE
18-70 years
Phase:
PHASE2
Brief Summary
Hernia repair is one of the most common operations. Whilst there are few complications, pain may last for several weeks and extend the period of convalescence. ALGRX 4975 is an ultra-pure form of caps...
Detailed Description
Inguinal hernia correction in adults is one of the most common operations with an annual rate of approximately 2,800 per 1 million people in the United States. Whilst there is little intra and postope...
Eligibility Criteria
Inclusion
- • The subject has a primary hernia and will undergo hernia repair by standard Lichtenstein mesh repair.
Exclusion
- The subject has undergone a lower abdomen surgical procedure in the past.
- The subject is currently scheduled to undergo bilateral inguinal hernia repair.
- Personal or familial contraindications in undergoing general anesthesia.
- Systolic blood pressure greater than 150 mmHg or diastolic greater than 95 mmHg
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00146198
Start Date
September 1 2005
End Date
February 1 2006
Last Update
December 20 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dagkirurgisk Klinik
Hørsholm, Denmark, DK-2970